Avery Therapeutics has filed a notice of an exempt offering of securities to raise $15,400,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Avery Therapeutics is raising up to $15,400,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Avery Therapeutics
Avery Therapeutics develops novel therapeutics intended to improve human life. The company is dedicated to creating immunomodulatory biologic therapeutics. Its work focuses on biologic treatments that modulate the immune system. Avery Therapeutics presents itself as a therapeutics company centered on innovative approaches to human healthcare. The website emphasizes its commitment to developing treatments with the potential to improve peoples lives.

To learn more, visit https://averythera.com/
LinkedIn: https://www.linkedin.com/company/averythera/

Contact:
Jordan Lancaster, Chief Executive Officer
https://www.linkedin.com/in/jrdnlancaster/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.